Dr. Philippe Bedard

Co-Principal Investigator, OCTANE

Dr. Philippe Bedard is the Co-Principal Investigator of the OICR-supported Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study. He is a Medical Oncologist at the Princess Margaret Cancer Centre, where he treats patients with breast and testicular cancers while researching new ways to detect and treat these diseases.

Dr. Bedard’s research interests include the use of prognostic gene expression profiles in early-stage breast cancer, neoadjuvant breast cancer clinical trials, and early drug development. He is the principal investigator for ongoing phase I and phase II clinical trials that include patients with breast cancer and other advanced solid malignancies.

Current affiliations

  • Co-Principal Investigator, Ontario-wide Cancer TArgeted Nucleic Acid Evaluation (OCTANE) study;
  • Staff Medical Oncologist, Princess Margaret Cancer Centre;
  • Associate Professor of Medicine, University of Toronto.

Research interests

  • Breast cancer;
  • Cancer of the urinary system;
  • Clinical genomics;
  • Clinical trial design;
  • New drug development;
  • Phase 1 trials;
  • Prognostic markers.

Select publications

Stockley T, Oza A, Berman H, Leighl N, Knox J, Shepherd F, Chen E, Krzyzanowska M, Dhani N, Joshua, A, Tsao M, Serra S, Clarke B, Roehrl M, Zhang T, Sukhai M, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim R, Razak A, Hansen A, Yu C, Pugh T, Kamel-Reid S, Siu L, Bedard P.
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Genome Med. 2016; 8(1):109.

Srikanthan A, Tran B, Beausoleil M, Jewett M, Hamilton R, Sturgeon J, O’Malley M, Anson-Cartwright L, Chung P, Warde P, Winquist E, Moore M, Amir E, Bedard P.
Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy.
J Clin Oncol. 2015; 33(6):582-587.

Bedard P, Tabernero J, Janku F, Wainberg Z, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Perez-Garcia J, Stathis A, Britten C, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa, C.
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors.
Clin Cancer Res. 2015; 21(4):730-8.

Bedard PL, Hansen AR, Ratain MJ, Siu LL.
Tumour heterogeneity in the clinic.
Nature. 2013; 501(7467):355-64.

See Dr. Bedard’s recent publications on PubMed or on Google Scholar.

Awards

  • Canadian Cancer Society Research Institute, William E. Rawls Prize, 2017;
  • University of Toronto, Department of Medicine, Individual teaching Excellence Award, 2014;
  • Conquer Cancer Foundation, Career Development Award, 2012-2014;
  • National Institutes of Health, NCI-CTEP National Institutes of Health Cancer Therapy Evaluation Program, Career Development Award, 2010-2011;
  • American Association for Cancer Research, AACR Translational Research Scholars Award, 2009.

Previous experience

  • MD, University of Toronto.

Related links

Opportunities to collaborate

To collaborate with Dr. Bedard, please contact him directly.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

Contact

Dr. Philippe Bedard
Philippe.Bedard@uhn.ca